Treatment (Rx) patterns and attrition rates in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Real world comparison of time-to-next-treatment (TTNT), ...

Recently, licensed and emerging treatments for metastatic ... a view to maximize survival as well. This article provides an overview of developments in advanced prostate cancer and considers ...

Overall survival between veterans with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone with kidney disease.

Real-world data support trial data on the use of lutetium-177 PSMA-617 in patients with PSMA-positive, metastatic castration-resistant prostate cancer.

Investigators report that estradiol works as well as luteinizing hormone–releasing hormone agonists for testosterone suppression and have a much better side-effect profile.

Providence Alaska Medical Center will be the first in the state to offer Pluvicto, an innovative therapy for metastatic ...

WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR) gene alterations, ...

Alarming Rise in Rates of Advanced Prostate Cancer ... An Early Blood Test Can Predict Survival in Patients With Metastatic Prostate Cancer Oct. 7, 2024 — A blood test, performed when metastatic ...

new medical technologies have introduced various anti-cancer treatments, progressively reducing BM incidence and enhancing long-term survival rates. Despite these advancements, some patients still ...

(HealthDay News) — For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR) gene alterations, talazoparib (TALA) + enzalutamide ...

Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...